{"meshTags":["Aged","Antineoplastic Agents","Cysts","Enzyme Inhibitors","Female","Gastrointestinal Neoplasms","Humans","Liver Neoplasms","Male","Middle Aged","Omentum","Peritoneal Neoplasms","Protein-Tyrosine Kinases","Stomach Neoplasms","Tomography, X-Ray Computed"],"meshMinor":["Aged","Antineoplastic Agents","Cysts","Enzyme Inhibitors","Female","Gastrointestinal Neoplasms","Humans","Liver Neoplasms","Male","Middle Aged","Omentum","Peritoneal Neoplasms","Protein-Tyrosine Kinases","Stomach Neoplasms","Tomography, X-Ray Computed"],"publicationTypes":["Clinical Trial","Journal Article","Randomized Controlled Trial"],"abstract":"The purpose of this article is to illustrate the CT findings in patients with hepatic metastases from a gastrointestinal stromal tumor who were treated with STI-571.\nHepatic metastases from gastrointestinal stromal tumors that respond to treatment with STI-571 can appear as near-cystic components with well-defined borders on contrast-enhanced CT. Most metastases became smaller. These metastases resemble simple cysts, but density measurements may differentiate them from one another.","title":"Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate).","pubmedId":"12239065"}